ENDRA Life Sciences Inc.
NDRA | NASDAQ
$6.31
+$0.81 (+14.73%)
At close: Sep 21, 2026, 4:00 PM ET
$6.38
+$0.07 (+1.09%)
Pre-market:
Sep 22, 2026, 7:22 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -5.76M | -10.82M | -10.52M | -13.16M | -11.5M | -11.5M |
Interest Income | n/a | n/a | n/a | n/a | n/a | 232.43 |
Pretax Income | -7.03M | -11.51M | -10.06M | -13.18M | -11.23M | -11.73M |
Net Income | -7.03M | -11.51M | -10.06M | -13.18M | -11.23M | -11.73M |
Selling & General & Admin | 3.91M | 7.63M | 5.52M | 6.6M | 6.02M | 5.58M |
Research & Development | 1.85M | 3.19M | 5M | 6.55M | 5.48M | 5.92M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | 8.84K |
Operating Expenses | 5.76M | 10.82M | 10.52M | 13.16M | 11.5M | 11.5M |
Interest Expense | n/a | n/a | n/a | 21.53K | n/a | 232.43K |
Selling & Marketing Expenses | 189.47K | 571.04K | 820.55K | 1.43M | 1.08M | 581.89K |
Cost & Expenses | 5.76M | 10.82M | 10.52M | 13.16M | 11.5M | 11.5M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 787.02K | 1.12M | 1.71M | 1.93M | 2.05M | 959.61K |
Shares Outstanding (Diluted) | 787.02K | 1.12M | 1.71M | 1.93M | 2.05M | 959.61K |
EPS (Basic) | -8.93 | -10.25 | -5.89 | -4.57 | -5.47 | -12.47 |
EPS (Diluted) | -8.93 | -10.25 | -5.89 | -6.84 | -5.47 | -12.47 |
EBITDA | -6.87M | -11.3M | -9.78M | -12.92M | -11.01M | -11.33M |
EBIT | -7.03M | -11.51M | -10.06M | -13.16M | -11.23M | -11.49M |
Depreciation & Amortization | 157.29K | 206.17K | 275.45K | 234.26K | 224.42K | 165.25K |
Add to Watchlist
Select watchlists to add or remove NDRA